Company / Cash & Equivalents
Corvus Pharmaceuticals, Inc. Cash & Equivalents History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$8.7M
FY2024
5-year range
$8.7M / $63.5M
FY2020-FY2024
Trend
-30.7%
vs FY2023
Sector context
#207 of 209
Health Care
What the data says
Among 209 Health Care companies, Corvus Pharmaceuticals, Inc. is in the bottom 1% for cash & equivalents. Cash & Equivalents has declined for 3 consecutive years, from $63M in FY2021 to $9M in FY2024.
Based on SEC 10-K filings.
$9M in FY2024 with a 5-year CAGR of +11.1%.
Declined from $13M to $9M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -48.4%
- 5-Year CAGR
- +11.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 1% in Health CareTop 99% of 209This company $8.7M Sector average $696.0M
▼
-98.7% below sector average
Key checks
Key Insights
- Corvus Pharmaceuticals, Inc.'s cash & equivalents has declined for 3 consecutive years.
- 5-year CAGR of +11.1%, indicating consistent growth.
- In FY2024, cash & equivalents decreased 30.7% year-over-year.
- Ranks #207 out of 209 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $8.7M | -30.7% |
| FY2023 | $12.6M | -4.1% |
| FY2022 | $13.2M | -79.3% |
| FY2021 | $63.5M | +285.6% |
| FY2020 | $16.5M | +219.3% |
| FY2019 | $5.2M | -86.9% |
| FY2018 | $39.2M | -13.1% |
| FY2017 | $45.1M | +793.2% |
| FY2016 | $5.0M | +23.0% |
| FY2015 | $4.1M | -67.2% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026